Drug therapy trials for the prevention of bronchopulmonary dysplasia: Current and future targets

Frontiers in Pediatrics

Volumn 2, Issue JUL, 2014, Pages

  Bhandari, Vineet ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic lung disease; Clinical trials; Drug therapy; Lung; Newborn

Indexed keywords

EID: 84994098075     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2014.00076     Document Type: Note

References (38)

1. Bhandari V, Bizzarro MJ, Shetty A, Zhong X, Page GP, Zhang H, et al. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics (2006) 117(6):1901-6. doi:10.1542/peds.2005-1414
2. Bhandari A, Bhandari V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics (2009) 123(6):1562-73. doi:10.1542/peds.2008-1962
3. Bhandari A, Bhandari V. "New" bronchopulmonary dysplasia-a clinical review. Clin Pulm Med (2011) 18:137-43. doi:10.1097/CPM.0b013e318218a071
4. Stroustrup A, Trasande L. Epidemiological characteristics and resource use in neonates with bronchopulmonary dysplasia: 1993-2006. Pediatrics (2010) 126(2):291-7. doi:10.1542/peds.2009-3456
5. Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, et al. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr (2005) 146(4):469-73. doi:10.1016/j.jpeds.2004.12.023
6. Trembath A, Laughon MM. Predictors of bronchopulmonary dysplasia. Clin Perinatol (2012) 39(3):585-601. doi:10.1016/j.clp.2012.06.014
7. Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol (2014) 100(3):145-57. doi:10.1002/bdra.23235
8. Johnson TJ, Patel AL, Jegier BJ, Engstrom JL, Meier PP. Cost of morbidities in very low birth weight infants. J Pediatr (2013) 162(2):243-49.e1. doi:10.1016/j.jpeds.2012.07.013
9. Bhandari A, Panitch HB. Pulmonary outcomes in bronchopulmonary dysplasia. Semin Perinatol (2006) 30(4):219-26. doi:10.1053/j.semperi.2006.05.009
10. Anderson PJ, Doyle LW. Neurodevelopmental outcome of bronchopulmonary dysplasia. Semin Perinatol (2006) 30(4):227-32. doi:10.1053/j.semperi.2006.05.010
11. Greenough A, Alexander J, Boorman J, Chetcuti PA, CliffI, Lenney W, et al. Respiratory morbidity, healthcare utilisation and cost of care at school age related to home oxygen status. Eur J Pediatr (2011) 170(8):969-75. doi:10.1007/s00431-010-1381-6
12. Landry JS, Croitoru D, Jin Y, Schwartzman K, Benedetti A, Menzies D. Health care utilization by preterm infants with respiratory complications in Quebec. Can Respir J (2012) 19(4):255-60
13. Gough A, Linden M, Spence D, Patterson CC, Halliday HL, McGarvey LP. Impaired lung function and health status in adult survivors of bronchopulmonary dysplasia. Eur Respir J (2014) 43(3):808-16. doi:10.1183/09031936.00039513
14. McEvoy CT, Jain L, Schmidt B, Abman S, Bancalari E, Aschner JL. Bronchopulmonary dysplasia: NHLBI workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc (2014) 11(Suppl 3):S146-53. doi:10.1513/AnnalsATS.201312-424LD
15. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. N Engl J Med (2006) 354(20):2112-21. doi:10.1056/NEJMoa054065
16. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med (2007) 357(19):1893-902. doi:10.1056/NEJMoa073679
17. Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos EV, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA (2012) 307(3):275-82. doi:10.1001/jama.2011.2024
18. Dayanim S, Lopez B, Maisonet TM, Grewal S, Londhe VA. Caffeine induces alveolar apoptosis in the hyperoxia-exposed developing mouse lung. Pediatr Res (2014) 75(3):395-402. doi:10.1038/pr.2013.233
19. Cole FS, Alleyne C, Barks JD, Boyle RJ, Carroll JL, Dokken D, et al. NIH consensus development conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics (2011) 127(2):363-9. doi:10.1542/peds.2010-3507
20. Kumar P. Use of inhaled nitric oxide in preterm infants. Pediatrics (2014) 133(1):164-70. doi:10.1542/peds.2013-3444
21. Davis PG, Schmidt B, Roberts RS, Doyle LW, Asztalos E, Haslam R, et al. Caffeine for apnea of prematurity trial: benefits may vary in subgroups. J Pediatr (2010) 156(3):382-7. doi:10.1016/j.jpeds.2009.09.069
22. Lavoie PM, Pham C, Jang KL. Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health. Pediatrics (2008) 122(3):479-85. doi:10.1542/peds.2007-2313
23. Prencipe G, Auriti C, Inglese R, Devito R, Ronchetti MP, Seganti G, et al. A polymorphism in the macrophage migration inhibitory factor promoter is associated with bronchopulmonary dysplasia. Pediatr Res (2011) 69(2):142-7. doi:10.1203/PDR.0b013e3182042496
24. Fujioka K, Shibata A, Yokota T, Koda T, Nagasaka M, Yagi M, et al. Association of a vascular endothelial growth factor polymorphism with the development of bronchopulmonary dysplasia in Japanese premature newborns. Sci Rep (2014) 4:4459. doi:10.1038/srep04459
25. Bhandari V. Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol (2014) 100(3):189-201. doi:10.1002/bdra.23220
26. Bhandari V. The potential of non-invasive ventilation to decrease BPD. Semin Perinatol (2013) 37(2):108-14. doi:10.1053/j.semperi.2013.01.007
27. Nold MF, Mangan NE, RudloffI, Cho SX, Shariatian N, Samarasinghe TD, et al. Interleukin-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. Proc Natl Acad Sci U S A (2013) 110(35):14384-9. doi:10.1073/pnas.1306859110
28. Harijith A, Choo-Wing R, Cataltepe S, Yasumatsu R, Aghai ZH, Janer J, et al. A role for matrix metalloproteinase 9 in IFNgamma-mediated injury in developing lungs: relevance to bronchopulmonary dysplasia. Am J Respir Cell Mol Biol (2011) 44(5):621-30. doi:10.1165/rcmb.2010-0058OC
29. Choo-Wing R, Syed MA, Harijith A, Bowen B, Pryhuber G, Janer C, et al. Hyperoxia and interferon-gamma-induced injury in developing lungs occur via cyclooxygenase-2 and the endoplasmic reticulum stress-dependent pathway. Am J Respir Cell Mol Biol (2013) 48(6):749-57. doi:10.1165/rcmb.2012-0381OC
30. Li Z, Choo-Wing R, Sun H, Sureshbabu A, Sakurai R, Rehan VK, et al. A potential role of the JNK pathway in hyperoxia-induced cell death, myofibroblast transdifferentiation and TGF-beta1-mediated injury in the developing murine lung. BMC Cell Biol (2011) 12(1):54. doi:10.1186/1471-2121-12-54
31. HilgendorffA, Parai K, Ertsey R, Juliana Rey-Parra G, Thebaud B, Tamosiuniene R, et al. Neonatal mice genetically modified to express the elastase inhibitor elafin are protected against the adverse effects of mechanical ventilation on lung growth. Am J Physiol Lung Cell Mol Physiol (2012) 303(3):L215-27. doi:10.1152/ajplung.00405.2011
32. Rehan VK, Torday JS. Exploiting the PTHrP signaling pathway to treat chronic lung disease. Drugs Today (Barc) (2007) 43(5):317-31. doi:10.1358/dot.2007.43.5.1062665
33. Morales E, Sakurai R, Husain S, Paek D, Gong M, Ibe B, et al. Nebulized PPARgamma agonists: a novel approach to augment neonatal lung maturation and injury repair in rats. Pediatr Res (2014) 75(5):631-40. doi:10.1038/pr.2014.8
34. Sun H, Choo-Wing R, Fan J, Leng L, Syed MA, Hare AA, et al. Small molecular modulation of macrophage migration inhibitory factor in the hyperoxia-induced mouse model of bronchopulmonary dysplasia. Respir Res (2013) 14:27. doi:10.1186/1465-9921-14-27
35. Sun H, Choo-Wing R, Sureshbabu A, Fan J, Leng L, Yu S, et al. A critical regulatory role for macrophage migration inhibitory factor in hyperoxia-induced injury in the developing murine lung. PLoS One (2013) 8(4):e60560. doi:10.1371/journal.pone.0060560
36. Fan C, Rajasekaran D, Syed MA, Leng L, Loria JP, Bhandari V, et al. MIF intersubunit disulfide mutant antagonist supports activation of CD74 by endogenous MIF trimer at physiologic concentrations. Proc Natl Acad Sci U S A (2013) 110(27):10994-9. doi:10.1073/pnas.1221817110
37. Sohn MH, Kang MJ, Matsuura H, Bhandari V, Chen NY, Lee CG, et al. The chitinase-like proteins breast regression protein-39 and YKL-40 regulate hyperoxia-induced acute lung injury. Am J Respir Crit Care Med (2010) 182(7):918-28. doi:10.1164/rccm.200912-1793OC
38. Syed MA, Bhandari V. Hyperoxia exacerbates postnatal inflammation-induced lung injury in neonatal BRP-39 null mutant mice promoting the M1 macrophage phenotype. Mediators Inflamm (2013) 2013:457189. doi:10.1155/2013/457189